


PHARMACEUTICAL 2021

CEN BIOTECH INC Rank 306 of 402







PHARMACEUTICAL 2021

CEN BIOTECH INC Rank 306 of 402



The relative strengths and weaknesses of CEN BIOTECH INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of CEN BIOTECH INC compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 203% points. The greatest weakness of CEN BIOTECH INC is the variable Liabilities, Current, reducing the Economic Capital Ratio by 261% points.

The company's Economic Capital Ratio, given in the ranking table, is -26%, being 73% points below the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	20
Cost of Goods Sold	0
Intangible Assets	4,956
Liabilities, Current	14,706
Liabilities, Non-Current	142
Other Assets	1,338
Other Compr. Net Income	0
Other Expenses	1,505
Other Liabilities	1,458
Other Net Income	16,793
Other Revenues	0
Property and Equipment	0
Research and Development	0
Selling, General and Administrative Expense	1,038

Output Variable	Value in 1000 USD
Assets	6,314
Liabilities	16,306
Expenses	2,544
Revenues	0
Stockholders Equity	-9,992
Net Income	14,250
Comprehensive Net Income	14,250
Economic Capital Ratio	-26%

